AptaBio Therapeutics Inc. specializes in the discovery and advancement of innovative therapeutic agents. Its core activities encompass developing specific inhibitors for the NOX enzyme family and crafting aptamer-based anti-cancer medicines. Additionally, the company supplies a range of transfection reagents, including Lipofector-Q, Lipofector-EXT, Lipofector-2000, Lipofector-EZ, and Lipofector-pMAX Reagent, which are utilized for introducing DNA or RNA into eukaryotic cells. Key drug candidates in its pipeline include PX-115, designed to address diabetic nephropathy; APX-1004, intended for diabetic retinopathy; and APX-311, targeting non-alcoholic steatohepatitis (NASH). Founded in 2009, AptaBio Therapeutics is headquartered in Yongin-Si, South Korea.